Clinicians
Creating a Functionally Validated, Personalized Treatment Plan for Every Patient
Encapsulate’s Tumor-on-a-Chip platforms leverage patient-derived tumoroids to recapitulate the native tumor microenvironment ex vivo.
By functionally validating phenotypic response to systemic therapies, you gain predictive efficacy data within 7 days of biopsy, minimizing time-to-treatment.
Every Cancer is Different
Encapsulate’s TOC assay correctly identifies the optimal treatment with accuracy, independent of the biopsy site, cancer type, clinical mutation, or stage of disease.
How It Works
Seamless Integration: Zero Clinical Workflow Disruption
Standard Sample Retrieval Day 0
We utilize a small tumor specimen from fresh biopsy tissue. No changes to your surgical or clinical workflow required.
Functional Testing Day 1-6
We replicate patient-derived tumoroids, preserving the 3D structure and native microenvironment, to screen against your selected therapies.
Actionable Clinical Report Day 7
You receive a clear functional analysis ranking therapeutic efficacy to guide your decision-making.
The Clinical Advantage
Confident, Informed Decisions
Move beyond uncertainty. Gain functional data that validates your therapy choice before treatment begins.
Data to Complement Genomics
Pair functional testing with genomic sequencing for a more complete picture of each patient’s therapeutic response.
Smarter, Targeted Care
Minimize exposure to ineffective toxicities. Identify the optimal therapy faster, even for complex or treatment-resistant cases.
Trusted by Leading Clinical Innovators:
Work with Encapsulate
Join the growing network of oncologists shaping the next generation of personalized cancer therapy.
Learn how Encapsulate’s technology can enhance your practice, improve patient outcomes, and bring precision medicine to life.